Silver Book

Silver Book Fact

Identifying individuals at high risk for developing AFib

Using simple bedside measures, identification of individuals at risk for developing atrial fibrillation is feasible. Selecting high-risk individuals for inclusion in atrial fibrillation prevention trials may also enhance prevention strategies.

Schnabel R, Sullivan L, Levy D, Pencina M, et al. Development of a Risk Score for Atrial Fibrillation (Framingham Heart Study): A community-based cohort study. Lancet. 2009; 373(9665): 739-45. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2809%2960443-8/abstract

Reference

Title
Development of a Risk Score for Atrial Fibrillation (Framingham Heart Study): A community-based cohort study
Publication
Lancet
Publication Date
2009
Authors
Schnabel R, Sullivan L, Levy D, Pencina M, et al
Volume & Issue
Volume 373, Issue 9665
Pages
739-45
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Atrial fibrillation ablation prevents recurrence of AFib
    Atrial fibrillation ablation, which involves using a catheter inserted into the heart to destroy electrical conduction tissue in or near the atria, prevents the recurrence of atrial fibrillation in up…  
  • Cost-savings associated with Warfarin use in AFib patients
    Warfarin use in Medicare patients with nonvalvular atrial fibrillation was independently associated with lower medical costs averaging $9,836 per patient, per year.  
  • Adjusted-dose warfarin reduced stroke risk in AFib patients
    Meta-analysis of randomized trials found that adjusted-dose warfarin reduced stroke risk in atrial fibrillation patients by 60%. Antiplatelet agents reduced risk by 20%.  
  • Effects of optimal anticoagulation among AFib patients
    If 50% of individuals with atrial fibrillation who do not receive prophylaxis were optimally anti-coagulated, 19,380 emboli would be prevented and $1.1 billion would be saved each year.  
  • Stroke risk reduction from thrombin inhibitor in AFib patients
    A recently approved direct thrombin inhibitor was found to reduce the risk of stroke/peripheral embolic events in atrial fibrillation patients by 34%, and the risk of hemorrhagic stroke by 74%—compared…